Comparing The Efficacy Between HBeAg Positive CHB And HBeAg Negative CHB Patients Both With METAVIR Scores?G2S2 Treated Using Pegylated-interferon ?

Background: Chronic hepatitis B(CHB)and related severe liver diseases caused by hepatitis B virus(HBV)infection still was the severe problems on public health worldwide.Antiviral treatment and prevention of related liver diseases is the key goal for patients with CHB,because these patients may have the potential danger of developed into significant fibrosis or hepatocellular carcinoma(HCC).Patients with CHB who need antiviral treatment according Clinical Practice Guidelines currently should meet the following: serum HBV DNA>2000 IU/ml,serum ALT levels ? 2ULN and/or moderate liver inflammation or fibrosis in liver tissue.Nevertheless,many CHB cases with normal or slightly elevated serum ALT have been found these patients with moderate or more inflammation and/or significant fibrosis even cirrhosis in their liver tissue.So,we think it would be much value for those patients with CHB,who has normal or slightly elevated serum ALT but METAVIR score?G2S2,to observe the clinical effect treated using pegylated interferon alfa(PegIFN-?).Objective: The aim of this study was to be comparing the efficacy between HBeAg positive CHB and HBeAg negative CHB patients both with normal or slightly elevated serum ALT but METAVIR score?G2S2 treated using PegIFN-? through retrospective analysis.Methods: A total of 81 cases fit into study including 38 cases of HBeAg(+)CHB and 43 cases of HBeAg(-)CHB.All of them had been received PegIFN-? therapy for 48 weeks.Data analysis was including serum ALT,serum HBV DNA,serum HBsAg,serum HBeAg,liver stiffness(LSM)before treatment and also including at 12 weeks,24weeks,36 weeks,and 48 weeks after treatment.Results:(1)The average age of patients with HBeAg(-)CHB was older than those patients with HBeAg(+)CHB.(2)Male cases were more than female in both groups.(3)HBV DNA and HBsAg level declined gradually than treated before in both groups during the treatment process using PegIFN-?.Further,we got the declining level of the baseline HBV DNA and HBsAg(as well as 12 weeks)between 12 weeks?24weeks?36weeks and 48 weeks respectively in both groups;and then,compared the declining level of HBV DNA and HBsAg between both groups.The results,we found,were slight better on patients with HBeAg(+)CHB than HBeAg(-)CHB at 48 weeks,but no significance difference on the virological response rate of both HBV DNA and HBsAg.(4)Liver LSM and serum ALT also showed some fluctuant changes than treated before in both groups during the treatment process using PegIFN-?,which suggested that PegIFN-? might have influence on liver LSM and serum ALT in both groups.(5)No serious adverse events during the process of treatment.Conclusion:(1)There were similar efficacy on the virological response rate of both HBV DNA and HBsAg between HBeAg positive CHB and HBeAg negative CHB patients,whom both with normal or slightly elevated serum ALT but METAVIR score?G2S2 treated using PegIFN-? 48 weeks through retrospective analysis.(2)According to our study,we think,CHB patients with normal or slightly elevated serum ALT but METAVIR score?G2S2 might be optimized patients for PegIFN-? treatment in the clinical real world;and Long-term follow-up will be required for long term clinical outcomes for these patients.